Contribution Of Muscle Cells And BM-derived APCs To CD8 T Cells Priming Upon SAM? Vaccination | 19690
Journal of Clinical & Cellular Immunology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
SAM? vaccines are self-amplifying mRNA derived from the positive-strand alphavirus genome. They contain genes encoding
non structural proteins which drive the RNA replication, but lack the viral structural proteins which are replaced by vaccine
antigens.In this way; RNA amplification within the cytoplasm of transfected cells allows an increase of antigen expression. In
addition, dsRNA intermediates exert an intrinsic adjuvant effect resulting in the induction of enhanced immune responses. It
has been shown that SAM? vaccines are effective at eliciting both humoral and cellular antigen-specific immune responses in
animal models of infectious and non-infectious diseases. However their mechanism of action has not been fully elucidated. To
date, no evidence of in vivo transduction of APCs by the SAM? vectors has been produced, while the antigen expression has
been shown to occur mostly in the muscle fibers. Bone marrow chimeric mice were used to assess the respective contribution
of muscle cells and bone marrow derived antigen presenting cells (APCs) to CD8 T cells priming following SAM?vaccination.
Our results show that bone marrow derived APCs rather than muscle cells are responsible for direct induction of Class-I
restricted CD8 T cells. Nevertheless, direct transfection of APCs by SAM? vectors is it not required for CD8 T cells priming,
suggesting that the antigen is expressed within muscle cells and then presentedby professional bone marrow derived APC to
CD8 T cells, most likely through a cross-priming.
Sattva S Neelapu is currently a tenured Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center,
Houston, Texas, USA. He completed his medical school at Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India
and Clinical Fellowship in Medical Oncology and Postdoctoral Fellowship in Tumor Immunology and Immunotherapy at the National Cancer Institute, National
Institutes of Health, Bethesda, Maryland. His research is focused on characterization of immunoregulatory mechanisms in the tumor microenvironment in patients
with lymphoma and developing strategies to target them.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals